Claudius Laurentius Henry Ii, NP-C Licensed Practical Nurse Medicare: Accepting Medicare Assignments Practice Location: 2312 Whitehorse Mercerville Rd, Suite 105, Mercerville, NJ 08619 Phone: 609-656-1100 |
News Archive
Many of the world's leading radiation oncologists are employing the unique capabilities of SBRT to treat a variety of cancers that often have defied conventional radiation therapy techniques. A multitude of studies evaluating SBRT are ongoing and investigators are publishing articles that demonstrate the effectiveness of this technique. Two studies led by renowned radiation oncologists were conducted at centers that use Elekta SBRT technology, and their results were published recently.
Usually, results from a new study help scientists inch their way toward an answer whether they are battling a health problem or are on the verge of a technological breakthrough. Once in a while, those results give them a giant leap forward. In a preliminary study in a canine model of Duchenne muscular dystrophy (DMD), University of Missouri scientists showed exactly such a leap using gene therapy to treat muscular dystrophy.
Ryan & Maniskas, LLP has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by members of the Board of Directors of BioSphere Medical, Inc. in connection with their actions in causing BioSphere Medical to enter into a merger agreement with Merit Medical System, Inc. and Merit BioAcquisition Co., a wholly-owned subsidiary of Merit Medical pursuant to which BioSphere Medical will merge with and into Merit BioAcquisition Co.
In a paper published in the July 11 online issue of Science Translational Medicine, researchers at the University of California, San Diego School of Medicine have identified two key regulatory proteins critical to clearing away misfolded proteins that accumulate and cause the progressive, deadly neurodegeneration of Huntington's disease.
The patent which is assigned to the University of Pittsburgh has been exclusively licensed to PRP. The drug, known as PulmoLAR, containing 2ME as active ingredient, is currently developed by PRP for the treatment of pulmonary arterial hypertension (PAH).
› Verified 6 days ago